US EditionBig pharma fears drugs in crosshairs of US-EU tarrif spat
- The Pharmaceutical Benefits Scheme creates delays in patient access to new medicines, with 'unreasonable patient access delays' occurring due to government considerations for public subsidy decisions.
- US companies are likely to push the Trump administration to act against Australian subsidies, viewing the PBS as a trade barrier, according to Australian National University law professor Peter Drahos.
- Trade Minister Don Farrell emphasized that the Labor Party would never compromise on the PBS amid trade tensions with the US.
- The PBS cost taxpayers $17.7 billion last financial year, helping reduce the cost of 930 different medicines, based on PBAC experts' public health decisions.
Insights by Ground AI
Does this summary seem wrong?
6 Articles
6 Articles
All
Left
4
Center
Right
1
Sydney Morning HeraldReposted by 
The Age
The AgeBig pharma’s plea to Trump to punish Australia for cheaper medicines
US medical giants say Australia’s Pharmaceutical Benefits Scheme is an “egregious and discriminatory” program that Trump should target in the next wave of tariffs.
·Sydney, Australia
Read Full Article
How shifting to big pharma is paying off for Clever Culture Systems
Clever Culture Systems’ pivot to target big pharma customers is proving a success Company has landed deals with Astra Zeneca and Bristol Myers Squibb Reported maiden half-year profit after income tax of $1.1m in H1 FY25 Special Report: It takes courage for a business to pivot – especially a publicly listed one answerable to shareholders – but biotech Clever Culture Systems has done just that, and the gamble seems to be paying off. Formerly LBT…
Coverage Details
Total News Sources6
Leaning Left4Leaning Right1Center0Last UpdatedBias Distribution80% Left
Bias Distribution
- 80% of the sources lean Left
80% Left
L 80%
R 20%
Factuality
To view factuality data please Upgrade to Premium
